TRAINING IN PHARMACOLOGY OF ANTINEOPLASTIC AGENTS

抗肿瘤药物药理学培训

• 批准号: 2720213
• 负责人: Andrew S Kraft
• 金额: $ 15.2万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-09-01 至 2004-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2720213
• 关键词: TRAINING; PHARMACOLOGY; ANTINEOPLASTIC; AGENTS

The Division of Medical Oncology, School of Pharmacy, and the Bone Marrow Transplant Program will sponsor an interdisciplinary postdoctoral training program in the "Clinical Pharmacology of Antineoplastic Agents." The goal of this training program is to provide individuals with the complex skills necessary to develop antineoplastic agents,e valuate their properties, design clinical studies, and move these agents through the regulatory agencies into national trials. The preceptors involved in this training believe that there is an important need for scientists who are trained in the practical evaluation of chemotherapeutic agents to facilitate the movement of these agents from the laboratory bench to the bedside. The Division of Medical Oncology, School of Pharmacy, and the Bone Marrow Transplant Program have exceptional research and clinical resources to train postdoctoral fellows in the complete range of skills which are necessary for the preclinical evaluation of antineoplastic agents, the design of clinical trials, and the scientific evaluation of the pharmacology. This training program will be open to Clinical Oncology Fellows who have completed one year of clinical training, and to Ph.D.s who have completed doctoral training in areas relevant to this program. The program will include 2-3 years of basic laboratory research training, required core courses, available lecture series, and elective courses. It will be administered by an Executive committee consisting of the directors of the three cooperating units, and student progress will be monitored by a Mentor's Committee of three faculty members. Trainees will be required to present an NIH style R0-1, local research seminars, attend national meetings, and publish articles in peer-reviewed journals. The trainee will be evaluated on a 6 month basis by the Program Director. This unique training program provides an interactive environment in which MDs and Ph.D.s involved in all phases of antineoplastic agent development will train individuals in the preclinical and clinical science necessary to take anti-cancer agents from the bench to the bedside.

药学院肿瘤内科和骨髓移植项目将赞助一个跨学科的博士后培训项目，即“抗肿瘤药物的临床药理学”。“这个培训计划的目标是为个人提供开发抗肿瘤药物所需的复杂技能，评估其特性，设计临床研究，并将这些药物通过监管机构进入国家试验。参与这项培训的导师认为，有一个重要的需要，科学家谁是在化疗药物的实际评估培训，以促进这些代理从实验室工作台到床边的运动。医学肿瘤学，药学院和骨髓移植计划的部门有特殊的研究和临床资源，以培养博士后研究员的完整技能范围，这是必要的临床前评估药物，临床试验的设计，和药理学的科学评估。本培训计划将开放给临床肿瘤学研究员谁已经完成了一年的临床培训，并向博士谁已经完成了博士培训领域相关的这个程序。该计划将包括2-3年的基础实验室研究培训，必要的核心课程，可用的系列讲座和选修课程。它将由三个合作单位的董事组成的执行委员会管理，学生的进步将由三名教师组成的导师委员会监督。学员将被要求提出一个NIH风格的R 0 -1，当地的研究研讨会，参加全国会议，并在同行评审的期刊上发表文章。培训生将由项目总监进行为期6个月的评估。这个独特的培训计划提供了一个互动的环境，其中参与抗癌药物开发所有阶段的MD和Ph.D.s将培训临床前和临床科学中的个人，这些科学是将抗癌药物从实验室带到床边所必需的。